Antiproliferative and Pro-Apoptotic Activity and Tubulin Dynamics Modulation of 1-Benzimidazol-2-yl Hydrazones in Human Breast Cancer Cell Line MDA-MB-231

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 May 25

PMID 38792260

Authors

Denitsa Yancheva

Maria Argirova

Irina Georgieva

Vanya Milanova

Maya Guncheva

Miroslav Rangelov

Nadezhda Todorova

Rumiana Tzoneva

Affiliations

Soon will be listed here.

Abstract

(1) Background: The aim of the work is the evaluation of in vitro antiproliferative and pro-apoptotic activity of four benzimidazole derivatives containing colchicine-like and catechol-like moieties with methyl group substitution in the benzimidazole ring against highly invasive breast cancer cell line MDA-MB-231 and their related impairment of tubulin dynamics. (2) Methods: The antiproliferative activity was assessed with the MTT assay. Alterations in tubulin polymerization were evaluated with an in vitro tubulin polymerization assay and a docking analysis. (3) Results: All derivatives showed time-dependent cytotoxicity with IC varying from 40 to 60 μM after 48 h and between 13 and 20 μM after 72 h. Immunofluorescent and DAPI staining revealed the pro-apoptotic potential of benzimidazole derivatives and their effect on tubulin dynamics in living cells. Compound prevented tubulin aggregation and blocked mitosis, highlighting the importance of the methyl group and the colchicine-like fragment. (4) Conclusions: The benzimidazole derivatives demonstrated moderate cytotoxicity towards MDA-MB-231 by retarding the initial phase of tubulin polymerization. The derivative containing a colchicine-like moiety and methyl group substitution in the benzimidazole ring showed potential as an antiproliferative agent and microtubule destabilizer by facilitating faster microtubule aggregation and disrupting cellular and nuclear integrity.

Citing Articles

Hydrazones, hydrazones-based coinage metal complexes, and their biological applications.

Tafere D, Gebrezgiabher M, Elemo F, Sani T, Atisme T, Ashebr T RSC Adv. 2025; 15(8):6191-6207.

PMID: 40034805 PMC: 11873977. DOI: 10.1039/d4ra07794f.

References

Uckun F, Cogle C, Lin T, Qazi S, Trieu V, Schiller G . A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Cancers (Basel). 2020; 12(1). PMC: 7016810. DOI: 10.3390/cancers12010074. View

Grisham R, Ky B, Tewari K, Chaplin D, Walker J . Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. Gynecol Oncol Res Pract. 2018; 5:1. PMC: 5756341. DOI: 10.1186/s40661-017-0058-5. View

Kamal A, Reddy T, Vishnuvardhan M, Nimbarte V, Rao A, Srinivasulu V . Synthesis of 2-aryl-1,2,4-oxadiazolo-benzimidazoles: Tubulin polymerization inhibitors and apoptosis inducing agents. Bioorg Med Chem. 2015; 23(15):4608-4623. DOI: 10.1016/j.bmc.2015.05.060. View

Blajeski A, Phan V, Kottke T, Kaufmann S . G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest. 2002; 110(1):91-9. PMC: 151025. DOI: 10.1172/JCI13275. View

Fanale D, Bronte G, Passiglia F, Calo V, Castiglia M, Di Piazza F . Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?. Anal Cell Pathol (Amst). 2015; 2015:690916. PMC: 4592889. DOI: 10.1155/2015/690916. View

Liang Y, Zhou Y, Deng S, Chen T . Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway. ChemMedChem. 2016; 11(20):2339-2346. DOI: 10.1002/cmdc.201600261. View

Gigant B, Wang C, Ravelli R, Roussi F, Steinmetz M, Curmi P . Structural basis for the regulation of tubulin by vinblastine. Nature. 2005; 435(7041):519-22. DOI: 10.1038/nature03566. View

Blay J, Papai Z, Tolcher A, Italiano A, Cupissol D, Lopez-Pousa A . Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(5):531-40. DOI: 10.1016/S1470-2045(15)70102-6. View

Husain A, Rashid M, ShaharYar M, Siddiqui A, Mishra R . Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: new anticancer agents. Eur J Med Chem. 2013; 62:785-98. DOI: 10.1016/j.ejmech.2012.07.011. View

10.

Othman D, Hamdi A, Tawfik S, Elgazar A, Mostafa A . Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition, and studies. J Enzyme Inhib Med Chem. 2023; 38(1):2166037. PMC: 9858449. DOI: 10.1080/14756366.2023.2166037. View

11.

Argirova M, Guncheva M, Momekov G, Cherneva E, Mihaylova R, Rangelov M . Modulation Effect on Tubulin Polymerization, Cytotoxicity and Antioxidant Activity of 1H-Benzimidazole-2-Yl Hydrazones. Molecules. 2023; 28(1). PMC: 9822270. DOI: 10.3390/molecules28010291. View

12.

Schaefer K . PPARgamma Inhibitors as Novel Tubulin-Targeting Agents. PPAR Res. 2008; 2008:785405. PMC: 2396401. DOI: 10.1155/2008/785405. View

13.

Bec A, Cindric M, Persoons L, Banjanac M, Radovanovic V, Daelemans D . Novel Biologically Active -Substituted Benzimidazole Derived Schiff Bases: Design, Synthesis, and Biological Evaluation. Molecules. 2023; 28(9). PMC: 10180076. DOI: 10.3390/molecules28093720. View

14.

Tahlan S, Kumar S, Kakkar S, Narasimhan B . Benzimidazole scaffolds as promising antiproliferative agents: a review. BMC Chem. 2019; 13(1):66. PMC: 6661752. DOI: 10.1186/s13065-019-0579-6. View

15.

Bryaskova R, Georgiev N, Philipova N, Bakov V, Anichina K, Argirova M . Novel Fluorescent Benzimidazole-Hydrazone-Loaded Micellar Carriers for Controlled Release: Impact on Cell Toxicity, Nuclear and Microtubule Alterations in Breast Cancer Cells. Pharmaceutics. 2023; 15(6). PMC: 10302270. DOI: 10.3390/pharmaceutics15061753. View

16.

ter Haar E, Day B, Rosenkranz H . Direct tubulin polymerization perturbation contributes significantly to the induction of micronuclei in vivo. Mutat Res. 1996; 350(2):331-7. DOI: 10.1016/0027-5107(95)00175-1. View

17.

Knossow M, Campanacci V, Ammar Khodja L, Gigant B . The Mechanism of Tubulin Assembly into Microtubules: Insights from Structural Studies. iScience. 2020; 23(9):101511. PMC: 7491153. DOI: 10.1016/j.isci.2020.101511. View

18.

Kumar A, Banerjee S, Roy P, Sondhi S, Sharma A . Solvent-free synthesis and anticancer activity evaluation of benzimidazole and perimidine derivatives. Mol Divers. 2017; 22(1):113-127. DOI: 10.1007/s11030-017-9790-3. View

19.

Ricart A, Ashton E, Cooney M, Sarantopoulos J, Brell J, Feldman M . A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011; 68(4):959-70. DOI: 10.1007/s00280-011-1565-4. View

20.

Kamal A, Rao A, Nayak V, Reddy N, Swapna K, Ramakrishna G . Synthesis and biological evaluation of imidazo[1,5-a]pyridine-benzimidazole hybrids as inhibitors of both tubulin polymerization and PI3K/Akt pathway. Org Biomol Chem. 2014; 12(48):9864-80. DOI: 10.1039/c4ob01930j. View